The 80-week Phase III study of 1,152 adults found nearly a third on the 12 mg dose lost 25% or more. Results appeared in The Lancet, and the drug is still unapproved.
Recap by typeshit. Full story at The Indian Practitioner.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
A projection framing weight loss drugs as a growing slice of American healthcare spending. Thin on detail beyond the market forecast.
The poster argues Mounjaro and Zepbound are getting easier to obtain and that coaches should watch for them on their teams. Only a short excerpt is available.
Loading…